|
US4666828A
(en)
|
1984-08-15 |
1987-05-19 |
The General Hospital Corporation |
Test for Huntington's disease
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4801531A
(en)
|
1985-04-17 |
1989-01-31 |
Biotechnology Research Partners, Ltd. |
Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
|
|
EP0308020A3
(en)
|
1987-09-18 |
1990-12-05 |
Merck & Co. Inc. |
5-(aryl and heteroaryl)-6-(aryl and heteroaryl)-1,2-dihydro-2-oxo 3-pyridinecarboxylic acids and derivatives thereof
|
|
US5272057A
(en)
|
1988-10-14 |
1993-12-21 |
Georgetown University |
Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
|
|
US5192659A
(en)
|
1989-08-25 |
1993-03-09 |
Genetype Ag |
Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
|
|
US5554630A
(en)
|
1993-03-24 |
1996-09-10 |
Neurosearch A/S |
Benzimidazole compounds
|
|
AU2682695A
(en)
|
1994-06-20 |
1996-01-15 |
Takeda Chemical Industries Ltd. |
Condensed imidazole compounds, their production and use
|
|
AU5348396A
(en)
|
1995-05-01 |
1996-11-21 |
Fujisawa Pharmaceutical Co., Ltd. |
Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
|
|
US6218529B1
(en)
|
1995-07-31 |
2001-04-17 |
Urocor, Inc. |
Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
|
|
WO1997012613A1
(en)
|
1995-10-05 |
1997-04-10 |
Warner-Lambert Company |
Method for treating and preventing inflammation and atherosclerosis
|
|
HU229024B1
(en)
|
1996-07-24 |
2013-07-29 |
Bristol Myers Squibb Pharma Co |
Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
|
|
CA2744096C
(en)
|
1996-07-31 |
2013-07-30 |
Laboratory Corporation Of America Holdings |
Biomarkers and targets for diagnosis, prognosis and management of prostate disease
|
|
JP2002501532A
(ja)
|
1997-05-30 |
2002-01-15 |
メルク エンド カンパニー インコーポレーテッド |
新規血管形成阻害薬
|
|
US5990146A
(en)
*
|
1997-08-20 |
1999-11-23 |
Warner-Lambert Company |
Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
|
|
US6465484B1
(en)
*
|
1997-09-26 |
2002-10-15 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
|
PL200939B1
(pl)
|
1998-01-28 |
2009-02-27 |
Bristol Myers Squibb Pharma Co |
Związki [1,5-a]-pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie tych związków
|
|
EP1109555A4
(en)
|
1998-08-31 |
2001-11-21 |
Merck & Co Inc |
Novel angiogenesis inhibitors
|
|
US6245759B1
(en)
|
1999-03-11 |
2001-06-12 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2001000207A1
(en)
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
|
AU5636900A
(en)
*
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
|
JP2003503354A
(ja)
|
1999-06-30 |
2003-01-28 |
メルク エンド カムパニー インコーポレーテッド |
Ｓｒｃキナーゼ阻害剤化合物
|
|
JP2001057292A
(ja)
|
1999-08-20 |
2001-02-27 |
Toray Ind Inc |
発光素子
|
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
|
GB9921150D0
(en)
|
1999-09-07 |
1999-11-10 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
WO2001021634A1
(en)
|
1999-09-21 |
2001-03-29 |
Lion Bioscience Ag |
Benzimidazole derivatives and combinatorial libraries thereof
|
|
GB9927687D0
(en)
|
1999-11-23 |
2000-01-19 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
ATE414079T1
(de)
|
2000-03-01 |
2008-11-15 |
Janssen Pharmaceutica Nv |
2,4-disubstituierte thiazolyl derivate
|
|
IL151517A0
(en)
|
2000-03-09 |
2003-04-10 |
Aventis Pharma Gmbh |
Therapeutic uses of ppar mediators
|
|
US20020041880A1
(en)
*
|
2000-07-05 |
2002-04-11 |
Defeo-Jones Deborah |
Method of treating cancer
|
|
JP2004519422A
(ja)
|
2000-08-04 |
2004-07-02 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン
|
|
AU2001295992A1
(en)
|
2000-10-24 |
2002-05-06 |
Sankyo Company Limited |
Imidazopyridine derivatives
|
|
GB0027561D0
(en)
|
2000-11-10 |
2000-12-27 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
WO2002046168A1
(en)
|
2000-12-07 |
2002-06-13 |
Astrazeneca Ab |
Therapeutic benzimidazole compounds
|
|
US20020107262A1
(en)
|
2000-12-08 |
2002-08-08 |
3M Innovative Properties Company |
Substituted imidazopyridines
|
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
|
SE0100568D0
(sv)
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
Compounds
|
|
BR0207096A
(pt)
|
2001-02-20 |
2004-01-20 |
Astrazeneca Ab |
Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3
|
|
SE0100567D0
(sv)
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
Compounds
|
|
TWI248936B
(en)
|
2001-03-21 |
2006-02-11 |
Merck Sharp & Dohme |
Imidazo-pyrimidine derivatives as ligands for GABA receptors
|
|
DE10117183A1
(de)
|
2001-04-05 |
2002-10-10 |
Gruenenthal Gmbh |
Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
|
|
JP4310109B2
(ja)
|
2001-04-26 |
2009-08-05 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
|
|
AU2002317377A1
(en)
|
2001-07-20 |
2003-03-03 |
Cancer Research Technology Limited |
Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
|
|
GB0128499D0
(en)
|
2001-11-28 |
2002-01-23 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
|
KR20040097375A
(ko)
*
|
2002-04-23 |
2004-11-17 |
시오노기 앤드 컴파니, 리미티드 |
피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
|
|
JP2004002826A
(ja)
|
2002-04-24 |
2004-01-08 |
Sankyo Co Ltd |
高分子イミダゾピリジン誘導体
|
|
EP1503757B1
(en)
|
2002-05-02 |
2007-12-19 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
AUPS251402A0
(en)
*
|
2002-05-23 |
2002-06-13 |
Cytopia Pty Ltd |
Kinase inhibitors
|
|
CA2486187C
(en)
*
|
2002-05-23 |
2013-02-19 |
Cytopia Pty Ltd. |
Kinase inhibitors
|
|
GB0212048D0
(en)
|
2002-05-24 |
2002-07-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
GB0212049D0
(en)
|
2002-05-24 |
2002-07-03 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
EP1511751B1
(en)
|
2002-06-04 |
2008-03-19 |
Neogenesis Pharmaceuticals, Inc. |
Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
|
|
US7196090B2
(en)
*
|
2002-07-25 |
2007-03-27 |
Warner-Lambert Company |
Kinase inhibitors
|
|
DE60317529T2
(de)
|
2002-09-19 |
2008-09-25 |
Schering Corp. |
Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
|
|
GB0223349D0
(en)
*
|
2002-10-08 |
2002-11-13 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
AU2003271185A1
(en)
|
2002-10-15 |
2004-05-04 |
Takeda Pharmaceutical Company Limited |
Imidazopyridine derivative, process for producing the same, and use
|
|
AU2003299651A1
(en)
|
2002-12-11 |
2004-06-30 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
|
US7262199B2
(en)
|
2002-12-11 |
2007-08-28 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US7826979B2
(en)
*
|
2003-02-14 |
2010-11-02 |
Vertex Pharmaceuticals Incorporated |
Method of modeling complex formation between a query ligan and a target molecule
|
|
US7476670B2
(en)
*
|
2003-02-18 |
2009-01-13 |
Aventis Pharma S.A. |
Purine derivatives, method for preparing, pharmaceutical compositions and novel use
|
|
US7157460B2
(en)
*
|
2003-02-20 |
2007-01-02 |
Sugen Inc. |
Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
|
|
EP2258365B1
(en)
|
2003-03-28 |
2013-05-29 |
Novartis Vaccines and Diagnostics, Inc. |
Use of organic compounds for immunopotentiation
|
|
US7442709B2
(en)
|
2003-08-21 |
2008-10-28 |
Osi Pharmaceuticals, Inc. |
N3-substituted imidazopyridine c-Kit inhibitors
|
|
KR20060119871A
(ko)
|
2003-08-21 |
2006-11-24 |
오에스아이 파마슈티컬스, 인코포레이티드 |
Ｎ３―치환된 이미다조피리딘 ｃ―ｋｉｔ 억제제
|
|
WO2005021531A1
(en)
*
|
2003-08-21 |
2005-03-10 |
Osi Pharmaceuticals, Inc. |
N-substituted benzimidazolyl c-kit inhibitors
|
|
NZ545694A
(en)
*
|
2003-12-03 |
2010-04-30 |
Ym Bioscience Australia Pty Lt |
Azole-based kinase inhibitors
|
|
JP2007519720A
(ja)
|
2004-01-28 |
2007-07-19 |
スミスクライン ビーチャム コーポレーション |
チアゾール化合物
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
CN1950372A
(zh)
|
2004-05-10 |
2007-04-18 |
万有制药株式会社 |
咪唑并吡啶化合物
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
CA2577947A1
(en)
|
2004-08-31 |
2006-03-09 |
Banyu Pharmaceutical Co., Ltd. |
Novel substituted imidazole derivative
|
|
CN101083985A
(zh)
|
2004-09-21 |
2007-12-05 |
幸讬制药公司 |
用于炎症及免疫相关用途的化合物
|
|
WO2006038001A1
(en)
|
2004-10-06 |
2006-04-13 |
Celltech R & D Limited |
Aminopyrimidine derivatives as jnk inhibitors
|
|
AR052419A1
(es)
*
|
2004-12-01 |
2007-03-21 |
Osi Pharm Inc |
Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit
|
|
WO2006070943A1
(ja)
|
2004-12-28 |
2006-07-06 |
Takeda Pharmaceutical Company Limited |
縮合イミダゾール化合物およびその用途
|
|
WO2006070198A1
(en)
|
2004-12-30 |
2006-07-06 |
Astex Therapeutics Limited |
Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
|
|
DOP2006000051A
(es)
|
2005-02-24 |
2006-08-31 |
Lilly Co Eli |
Inhibidores de vegf-r2 y métodos
|
|
US7998974B2
(en)
|
2005-03-03 |
2011-08-16 |
Sirtris Pharmaceuticals, Inc. |
Fused heterocyclic compounds and their use as sirtuin modulators
|
|
WO2006108103A1
(en)
|
2005-04-05 |
2006-10-12 |
Pharmacopeia, Inc. |
Purine and imidazopyridine derivatives for immunosuppression
|
|
FR2884821B1
(fr)
*
|
2005-04-26 |
2007-07-06 |
Aventis Pharma Sa |
Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation
|
|
US7572807B2
(en)
|
2005-06-09 |
2009-08-11 |
Bristol-Myers Squibb Company |
Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
|
|
WO2007036732A1
(en)
|
2005-09-30 |
2007-04-05 |
Astrazeneca Ab |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
|
AU2007227210A1
(en)
|
2006-03-20 |
2007-09-27 |
Synta Pharmaceuticals Corp. |
Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
|
|
CA2646886A1
(en)
|
2006-03-23 |
2007-10-04 |
Synta Pharmaceuticals Corp. |
Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
|
|
ITVA20060041A1
(it)
|
2006-07-05 |
2008-01-06 |
Dialectica Srl |
Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
|
|
TW200811134A
(en)
|
2006-07-12 |
2008-03-01 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
EP1882475A1
(en)
|
2006-07-26 |
2008-01-30 |
Novartis AG |
Method of treating disorders mediated by the fibroblast growth factor receptor
|
|
US7737149B2
(en)
|
2006-12-21 |
2010-06-15 |
Astrazeneca Ab |
N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
|
|
JP5442449B2
(ja)
*
|
2006-12-22 |
2014-03-12 |
アステックス、セラピューティックス、リミテッド |
新規化合物
|
|
US8131527B1
(en)
|
2006-12-22 |
2012-03-06 |
Astex Therapeutics Ltd. |
FGFR pharmacophore compounds
|
|
EP2114941B1
(en)
|
2006-12-22 |
2015-03-25 |
Astex Therapeutics Limited |
Bicyclic heterocyclic compounds as fgfr inhibitors
|
|
US7977336B2
(en)
|
2006-12-28 |
2011-07-12 |
Banyu Pharmaceutical Co. Ltd |
Aminopyrimidine derivatives as PLK1 inhibitors
|
|
NZ580327A
(en)
|
2007-04-03 |
2012-02-24 |
Array Biopharma Inc |
IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
|
|
CA2934114A1
(en)
|
2007-06-12 |
2008-12-18 |
Achaogen, Inc. |
Antibacterial agents
|
|
EP2170882A1
(en)
|
2007-06-26 |
2010-04-07 |
Gilead Colorado, Inc. |
Imidazopyridinyl thiazolyl histone deacetylase inhibitors
|
|
GB0720041D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New Compounds
|
|
GB0720038D0
(en)
|
2007-10-12 |
2007-11-21 |
Astex Therapeutics Ltd |
New compounds
|
|
GB0810902D0
(en)
|
2008-06-13 |
2008-07-23 |
Astex Therapeutics Ltd |
New compounds
|
|
GB0906470D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|
|
GB0906472D0
(en)
|
2009-04-15 |
2009-05-20 |
Astex Therapeutics Ltd |
New compounds
|